Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17883728 | 0.96 | RAB9A (0.36) | RAB9APDK1PDK2PDK3PDK4 | |
| SCHEMBL17879784 | 0.91 | RAB9A (0.35) | RAB9APDK1PDK2PDK3PDK4 | |
| SCHEMBL17879783 | 0.87 | L3MBTL1 (0.39) | ALDH1A1KDM4EHPGDHSD17B10HRH3 | |
| SCHEMBL20110624 | 0.85 | — | — | |
| SCHEMBL17879737 | 0.84 | L3MBTL1 (0.33) | RAB9AALDH1A1KDM4EHPGDTDP1 | |
| SCHEMBL17879734 | 0.84 | L3MBTL1 (0.35) | RAB9AALDH1A1KDM4EHPGDHRH3 | |
| SCHEMBL17883520 | 0.83 | RAB9A (0.36) | RAB9APDK1PDK2PDK3PDK4 | |
| SCHEMBL17879733 | 0.82 | LCK (0.36) | RAB9APDK1PDK2PDK3PDK4 | |
| SCHEMBL17879763 | 0.81 | KCNJ11 (0.32) | — | |
| SCHEMBL18807400 | 0.80 | SERPINE1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10007179-B2 | Thermal acid generators and photoresist pattern trimming compositions and methods | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-9696629-B2 | Photoresist pattern trimming compositions and methods | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170123314-A1 | THERMAL ACID GENERATORS AND PHOTORESIST PATTERN TRIMMING COMPOSITIONS AND METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170123313-A1 | THERMAL ACID GENERATORS AND PHOTORESIST PATTERN TRIMMING COMPOSITIONS AND METHODS | ROHM & HAAS ELECT MAT (US) | 2017-05-04 | — | — | US | disclosed |
| US-20160187783-A1 | PHOTORESIST PATTERN TRIMMING COMPOSITIONS AND METHODS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170123313-A1 | THERMAL ACID GENERATORS AND PHOTORESIST PATTERN TRIMMING COMPOSITIONS AND METHODS | ADH1A, ADH1C, FPR1 | RAB9A 4598/4885PDK1 3886/4885PDK2 3223/4885 |
| US-10007179-B2 | Thermal acid generators and photoresist pattern trimming compositions and methods | ADH1A, PUF60, PARG | RAB9A 3794/4885PDK1 3570/4885PDK2 2431/4885 |
| US-20170123314-A1 | THERMAL ACID GENERATORS AND PHOTORESIST PATTERN TRIMMING COMPOSITIONS AND METHODS | ADH1A, PUF60, PARG | RAB9A 3794/4885PDK1 3570/4885PDK2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.